OHSU

Medical Directors

Christopher Corless, MD, PhD

Christopher Corless

Executive Director and Chief Medical Officer, Knight Diagnostic Laboratories Oregon Health & Science University
Professor of Pathology, OHSU

Dr. Corless received his M.D. and Ph.D. from Washington University in St. Louis, Mo. He did his residency training in anatomic pathology at Brigham & Women's Hospital in Boston, Mass., where he also completed fellowships in gastrointestinal and genitourinary pathology. Dr. Corless is board certified in anatomic pathology. He joined the faculty of Oregon Health & Science University in 1994 and became professor of pathology in 2004.

Dr. Corless has served as the residency program director in the Department of Pathology and medical director of surgical pathology for OHSU Hospital. In addition to practicing surgical pathology, Dr. Corless has expertise in applying molecular diagnostics to the classification and prognostication of solid tumors. He has a longstanding research interest in gastrointestinal stromal tumors (GISTs), as well as in bringing new technologies into clinical use. Dr. Corless has authored or coauthored more than 200 publications.


Cary O. Harding, MD, FACGM

Cary O. Harding

Director, Biochemical Genetics Laboratory, Knight Diagnostic Laboratories,
Associate Professor of Molecular and Medical Genetics and Pediatrics, OHSU

Dr. Harding received his medical degree from the University of Washington School of Medicine in Seattle, Wash. He completed a pediatrics residency at the University of Wisconsin in Madison, Wis., where he also did fellowships in clinical and biochemical genetics. Dr. Harding is board certified in Pediatrics, Clinical Genetics, Biochemical Genetics, and is a Founding Fellow of the American College of Medical Genetics (ACMG). He joined the faculty of Oregon Health & Science University in 1999. In addition to his role as the Medical Director of the Biochemical Genetics Laboratory in the Knight Diagnostic Laboratories, Dr. Harding attends in both the Pediatric Genetics and Pediatric Metabolism clinics at Doernbecher Children’s Hospital. He serves as a consultant to the Northwest Regional Newborn Screening Program and as the Treasurer for the Society for Inherited Metabolic Disorders (SIMD). Dr. Harding’s research laboratory is developing novel therapies, including gene and cell therapies, for the treatment of inborn errors of metabolism.

SUSAN J. HAYFLICK, M.D.

Hayflick, Susan

Professor and Chairman of Molecular and Medical Genetics
Professor of Pediatrics and Neurology, OHSU

Dr. Hayflick received her M.D. from The Pennsylvania State University College of Medicine in Hershey, Pa. She completed her residency in pediatrics at the Maine Medical Center in Portland, Maine, and a fellowship in medical genetics at the Johns Hopkins Hospital in Baltimore, Maryland. Dr. Hayflick is ABMG-certified in clinical, biochemical and molecular genetics. She joined the faculty of Oregon Health & Science University in 1993 and has built a research and clinical program of international prominence in neurodegeneration with brain iron accumulation (NBIA). Dr. Hayflick’s expertise in neurogenetics has led to global leadership of the Knight Diagnostic Laboratories in testing for rare disorders.

Dr. Hayflick directs the OHSU Human Genetics Initiative and the Rare Disorders Research Consortium, and is Chair of the Department of Molecular and Medical Genetics.


Stephen Robert Moore, PhD, FACMG

Moore, Steve

Director, Cytogenetics Laboratory, and Director, Medical Genetics Laboratory,Knight Diagnostics Laboratories
Assistant Professor, Molecular and Medical Genetics, OHSU

Dr. Moore is ABMG board certified in both Clinical Cytogenetics and Clinical Molecular Genetics, completing fellowships at Cedars-Sinai/UCLA and OHSU respectively, and is a fellow of the American College of Medical Genetics. Dr. Moore received his M.S. in Biology from California State University, and his Ph.D. in Environmental Toxicology from the University of California. He was a Career Development Fellow with the Medical Research Council (MRC) Radiation and Genome Stability Unit in Harwell, UK, the Gray Laboratory, and the MRC Molecular Hematology Laboratory (U. Oxford), where he developed chromosomal assays and targeted radiation techniques for studying long-term effects of radiation exposure, also a focus of his Ph.D. research. Dr. Moore had a short fellowship at City of Hope developing tools for chromosomal microarray analysis of single cells. Presently, his laboratory interests include chromosomal microarray analysis for postnatal, prenatal and oncology applications and the development of next-generation sequencing panels rare genetic disorders; the overarching goal being to provide genomic tools to guide personalized medicine into the future. Dr. Moore joined the faculty of Oregon Health & Science University in 2009.


Susan Olson, Ph.D.

Olson, Susan

Director, Cytogenetics Laboratory, Knight Diagnostic Laboratories Oregon Health & Science University Professor of Molecular and Medical Genetics, OHSU

Dr. Olson earned her Ph.D. in medical genetics from OHSU and is certified by the American Board of Medical Genetics, with subspecialties in Clinical Cytogenetics. Dr. Olson was elected to the founding board of directors for the American Cytogenetics Conference and is a Founding Fellow of the American College of Medical Genetics. She joined the OHSU faculty in 1987 where she currently serves on the steering committee for the Program in Molecular and Cellular Biosciences, the School of Medicine Curriculum Committee, the Oregon Stem Cell Oversight Committee and the OHSU Collaborative Research Leadership Group.

Dr. Olson’s research interests include mechanisms of genomic instability and cancer. In particular, the cancer predisposing syndrome Fanconi anemia, which is a recessive disorder of DNA repair that has the classic finding of chromosome breakage. Dr. Olson is also Director of the OHSU Cytogenetics Research Service Laboratory which offers traditional and molecular cytogenetic analysis of human, mouse and other animals to investigators throughout the country.


RICHARD D. PRESS, M.D., PH.D.

Press, Rick

Director, Molecular Pathology and Molecular Diagnostics Laboratories, Knight Diagnostic Laboratories, Oregon Health & Science University Professor of Pathology, OHSU

Dr. Press received his M.D.and Ph.D. from Case Western Reserve University in Cleveland, Ohio. He completed his pathology and molecular pathology residencies at the University of Pennslyvania. Dr. Press is board-certified in Clinical Pathology and Molecular Genetic Pathology.

Dr. Press is the program director for the Molecular Genetic Pathology Fellowship. His research interests include molecular diagnostic biomarkers in cancer, infectious diseases and prevalent genetic alterations in common diseases. He has authored or co-authored more than 90 publications.


Sue Richards, Ph.D.

Richards, Sue

Director, Molecular Genetics Laboratory, Knight Diagnostic Laboratories Oregon Health & Science University Professor of Molecular and Medical Genetics, OHSU

Dr. Richards received her Ph.D. from Baylor College of Medicine in Houston, Texas and did postdoctoral fellowships at the University of Texas Southwestern Medical Center and Howard Hughes Medical Institute in Dallas, Texas. She is ABMG board certified in Clinical Molecular Genetics and a Founding Fellow of the American College of Medical Genetics. Following her training, Dr. Richards directed the Baylor DNA Diagnostic Laboratory and the Diagnostic Sequencing Laboratory for a number of years. Dr. Richards joined the faculty of Oregon Health & Science University in 2003 as a Professor in the Department of Molecular and Medical Genetics. She has been actively engaged in EGAPP (Evaluation of Genomic Applications in Practice and Prevention) since 2005. In 2006 she was elected as the clinical molecular genetics representative on the Board of Directors for the American College of Medical Genetics and Genomics (ACMG).

Nationally, Dr. Richards is active in quality assurance for genetic testing through development of standards and guidelines, as well as methods-based proficiency testing for laboratories sequencing genes of rare disorders. She chaired the ACMG Laboratory Quality Assurance Committee that develops standards and guidelines for clinical genetic laboratories, and currently chairs the Molecular Subcommittee focusing on development of standards and guidelines for molecular tests. Dr. Richards is Vice Chair of the College of American Pathologists (CAP)/ACMG Biochemical and Molecular Resource Committee that develops and reviews external proficiency testing (PT) for molecular genetics tests, and oversees the new methods-based PT survey for sequencing tests. Additionally, she has also served as a faculty member of the ACMG Board Review Course for several years.


George Thomas, M.D.

George Thomas

Associate Director, Molecular Pathology and Molecular Diagnostics Laboratories

George Thomas is a surgical pathologist, with clinical and research interests in prostate, kidney and bladder cancers. After completing medical school in Ireland, George continued his training at the Harvard and UCLA pathology programs. He was on the faculty at UCLA before joining OHSU. His laboratory works on decoding how targeted cancer drugs work and uses this knowledge to individualize cancer treatments.

EDUCATION

  • Degree: M.D., Royal College of Surgeons, Dublin, Ireland, 1991
  • Residency: Anatomic Pathology, UCLA, 2001 Anatomic Pathology, Beth Israel Deaconess Medical Center, Harvard, 1999
  • Fellowship: Research, UCLA, 2004